Product Introduction
Zymoflam Tablet is a medicine designed to relieve pain and inflammation. It is commonly used for conditions such as arthritis-related discomfort, muscle sprains, injuries, fractures, and post-surgical swelling.
The tablet can be taken with or without food. The dosage and duration depend on the condition being treated and how well your symptoms respond. Continue using it as prescribed by your doctor and do not stop the medication without consulting them.
Uses
Relief from pain and inflammation caused by injury, surgery, or chronic conditions
Management of arthritis-related pain and joint discomfort
Benefits
Zymoflam Tablet combines enzymes and antioxidants to support pain relief and reduce inflammation. It is effective in conditions affecting muscles and joints, such as osteoarthritis and rheumatoid arthritis. The formulation promotes faster recovery and helps you maintain an active lifestyle with reduced discomfort.
How It Works
Zymoflam Tablet contains Bromelain and Trypsin, which are enzymes that improve blood flow to affected areas and assist the body in reducing pain and swelling. It also contains Rutoside, an antioxidant that protects tissues from damage caused by free radicals and further decreases inflammation.
How to Use
Take Zymoflam Tablet as prescribed by your healthcare provider.
Swallow the tablet whole; do not chew, crush, or break it.
It may be taken with or without food, ideally at a consistent time each day for optimal effect.
Side Effects
Most people tolerate Zymoflam Tablet well. Side effects are uncommon, but if you notice any unusual symptoms, contact your doctor promptly.
Precautions
Alcohol: Consult your doctor before consuming alcohol while on this medication.
Pregnancy & Breastfeeding: Speak to your healthcare provider before use.
Driving: Avoid driving if you experience symptoms that affect focus or reaction time.
Kidney & Liver Conditions: Use with caution in patients with severe kidney or liver disease; dose adjustments may be required.
Reviews
There are no reviews yet.